271 completed, 55 recruiting, 51 terminated, 51 unknown. 154 Phase 2, 139 Phase 3, 110 Phase 1, 61 Phase 4, 30 Not applicable.
Follow tocilizumab: new trials by email Literature Review of tocilizumab trials Research Report on tocilizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-Interleukin-6 (IL6) in Calciphylaxis Tocilizumab - Calciphylaxis | Phase 1 | Not yet recruiting | Boston Medical Center | 10 | 2027-09-01 | 2026-07-16 |
| A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis | Phase 3 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 92 | 2027-02-03 | 2026-09-18 |
| TCR1188-ABC Cells in KRAS-mutated Cancers TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab - Cholangiocarcinoma, Colorectal Cancer | Phase 1 | Recruiting | University of Pennsylvania | 30 | 2026-12-01 | 2026-10-14 |
| COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" Anakinra, Tocilizumab, Standard medical treatment - New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus | Phase 3 | Not yet recruiting | Yale University | 438 | 2026-12-01 | 2026-08-19 |
| Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder Tocilizumab, Placebo, Whole-Body Hyperthermia - Major Depressive Disorder | Phase 2 | Suspended | Massachusetts General Hospital | 35 | 2026-12-01 | 2025-11-13 |
| A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) MK-6255, CD8 PET Tracer, Acetaminophen - Ovarian Neoplasms, Endometrial Neoplasms | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 80 | 2026-11-13 | 2026-10-13 |
| Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older Anakinra, Biospecimen Collection, Computed Tomography - Melanoma | Phase 1 | Not yet recruiting | University of Southern California | 40 | 2026-11-01 | 2026-09-24 |
| Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy - Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 43 | 2026-11-01 | 2026-10-30 |
| To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Cevostamab, Tocilizumab - Lupus Erythematosus, Systemic | Phase 1 | Recruiting | Genentech, Inc. | 46 | 2026-10-31 | 2026-10-06 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | Hoffmann-La Roche | 45 | 2026-10-30 | 2026-10-15 |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 60 | 2026-10-09 | 2026-10-08 |
| Clinical Features and Treatment of Systemic JIA in Children Tocilizumab (Actemra®) - Systemic Juvenile Idiopathic Arthritis (sJIA), Systemic Juvenile Idiopathic Arthritis | Not yet recruiting | Sohag University | 50 | 2026-10-01 | 2026-09-11 | |
| Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE Tociliuzumab, Placebo - Acute Ischemic Stroke | Phase 2 / Phase 3 | Not yet recruiting | Oslo University Hospital | 156 | 2026-09-21 | 2026-10-13 |
| Treatment Strategy for Patients With RA-ILD Tocilizumab, Rituximab (RTX), Methotrexate - Rheumatoid Arthritis Associated Interstitial Lung Disease | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | 204 | 2026-09-20 | 2026-09-03 |
| Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis Etanercept, Adalimumab, Upadacitinib - Arthritis, Rheumatoid | Not yet recruiting | Tufts Medical Center | 18 | 2026-09-01 | 2026-07-22 | |
| Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma Atezolizumab, Bevacizumab, Tocilizumab - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | CHA University | 51 | 2026-09-01 | 2026-08-19 |
| A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients CC-97540 (BMS-986353), Fludarabine, Cyclophosphamide - AQP4+ NMOSD | Phase 1 | Not yet recruiting | University of Texas Southwestern Medical Center | 5 | 2026-09-01 | 2026-07-17 |
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 46 | 2026-09-01 | 2026-09-04 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-10-27 |
| Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial Tocilizumab, Baricitinib, Anakinra - Sepsis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 2000 | 2026-07-09 | 2026-10-20 |
Showing 20 of 501. Sign in to see all of them.
Arthritis, Rheumatoid (165) · COVID-19 (46) · Arthritis, Juvenile (24) · Multiple Myeloma (16) · Cytokine Release Syndrome (14) · Giant Cell Arteritis (13) · Inflammation (12) · Lymphoma, Non-Hodgkin (10) · Pneumonia (9) · Carcinoma, Non-Small-Cell Lung (8) · Coronavirus Infections (8) · Breast Neoplasms (7) · Takayasu Arteritis (7) · Lupus Erythematosus, Systemic (6) · Recurrence (6)
Hoffmann-La Roche (170) · Assistance Publique - Hôpitaux de Paris (16) · Chugai Pharmaceutical (13) · Genentech, Inc. (11) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Copenhagen University Hospital, Rigshospitalet (4) · Massachusetts General Hospital (4) · Oslo University Hospital (4) · Peking Union Medical College Hospital (4) · AO GENERIUM (3) · Bio-Thera Solutions (3) · Brigham and Women's Hospital (3) · Capital Medical University (3) · Duke University (3) · Herlev Hospital (3)
United States (180) · France (97) · Spain (91) · Italy (64) · United Kingdom (61) · Germany (57) · Canada (55) · Australia (53) · China (51) · Denmark (48) · Belgium (40) · Poland (38) · Brazil (36) · Israel (35) · Netherlands (33)
Takahiro Kakehi (11) · Lindi Jiang, PhD (3) · Oksana A. Markova, MD (3) · Akter Kamal, MD, PhD (2) · Fu-Dong Shi, MD,PhD (2) · Ronald van Vollenhoven, MD, Prof. (2) · William R Drobyski, MD (2) · Yuji Kimura (2)
PMID 29244149, PMID 30649524, PMID 22491018, PMID 24429164, PMID 32453485, PMID 18358927, PMID 23765873, PMID 24634205, PMID 24786929, PMID 27909081, PMID 28376912, PMID 28955499, PMID 30590833, PMID 30824645, PMID 31043095, PMID 32508063, PMID 32912276, PMID 33201228, PMID 33294861, PMID 33394942, PMID 33506875, PMID 34473343, PMID 34612846, PMID 37328287, PMID 37489818, PMID 40198544, PMID 40749164, PMID 42283231, PMID 42836590, PMID 14558057, PMID 16368644, PMID 17487675, PMID 1750226, PMID 18358926, PMID 18625622, PMID 18821691, PMID 19297346, PMID 20039425, PMID 21360490, PMID 21949007, PMID 22373834, PMID 22397953, PMID 22562983, PMID 22674883, PMID 22753773, PMID 22907572, PMID 22972745, PMID 23252525, PMID 23305631, PMID 23322466
2023 (14), 2009 (11), 2008 (8), 2016 (7), 2018 (7), 2017 (6), 2019 (6), 2014 (5), 2015 (5), 2025 (5), P30CA138292 (2), 1UG3CA283652-01 (1), K08HL143189 (1), P30CA008748 (1), P30CA014089 (1)